Hu, Xiaojie
Li, Wenbin
Zeng, Kang
Xu, Zhongyuan
Li, Changxing
Kang, Zhuang
Li, Shenglan
Huang, Xin
Han, Pu
Lin, Hongmei
Hui, Ai-Min
Tan, Yan
Diao, Lei
Li, Ben
Wang, Xingli
Wu, Zhuli
Lin, Xiaoxi
Funding for this research was provided by:
Shanghai Fosun Pharmaceutical Development Co., Ltd.
Article History
Received: 27 October 2022
Accepted: 7 June 2023
First Online: 3 July 2023
Declarations
:
: The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines and with the approval of the Institutional Review Board at the leading study site (Shanghai Ninth People's Hospital, approval number SH9H-2020-C25-6). All patients provided written informed consent to participate.
: Not applicable.
: XH, PH, HL, YT, LD, BL and XW are employees of Fosun Pharma and declare no stock ownership in Fosun Pharma. ZW have stock ownership in Fosun Pharma. AH is a former Fosun pharma employee. All other authors have no conflicts of interest to declare.